What Is The Leading Driver Behind Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipation Treatment Market Market Expansion in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Opioid-Induced Constipation Treatment Industry Market Size Be by 2025?
Strong expansion has characterized the opioid-induced constipation treatment market recently; projections indicate this will continue, moving from a value of $1.78 billion in the year 2024 to $1.9 billion in 2025, reflecting a compound annual growth rate of 6.7%. Factors credited with fueling this past momentum include the increasing size of the elderly demographic, the development of tailored OIC therapies, wider access to successful OIC pharmaceuticals, the greater incidence of opioid consumption, and the growing rate of gastrointestinal ailments.

What's the Long-Term Growth Forecast for the Opioid-Induced Constipation Treatment Market Size Through 2029?
Anticipation surrounds the opioid-induced constipation treatment sector, projecting robust expansion ahead; by 2029, this market is forecasted to achieve a valuation of $2.42 billion, propelled by a compound annual growth rate (CAGR) of 6.3%. This upward trajectory across the projection timeframe stems from several key factors: swifter drug approval processes, a rise in opioid analgesic script utilization, escalating financial commitment toward researching and developing new remedies, and the advancement of biologic therapies. Significant developments shaping this period involve elevating patient understanding and recognition, the introduction of therapies focused on specific mechanisms, the application of non-drug-based management approaches, breakthroughs in biotech innovation, and augmented levels of funding.

View the full report here:
https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

What Are the Key Growth Drivers Fueling the Opioid-Induced Constipation Treatment Market Expansion?
The increasing prescription of opioids to address both oncological and non-oncological pain syndromes is anticipated to fuel the expansion of the market dedicated to treating opioid-induced constipation. This necessity to manage pain that is moderate to severe, stemming from cancer or other unrelated conditions, is rooted in considerations like pain severity and persistence, individual patient reactions to alternative therapies, and the overarching objective of enhancing life quality while mitigating risks associated with addiction and adverse effects. Treatments for OIC provide crucial symptomatic relief for individuals receiving opioids for cancer or non-cancer pain by alleviating the resulting bowel inactivity, thus boosting patient comfort, compliance with prescribed pain protocols, and general well-being without interfering with the effectiveness of pain management. To illustrate the prevalence, data from the Government of Canada indicated in May 2021 that the number of Canadians facing chronic pain might climb to 8.3 million by 2025, potentially escalating further to 9.0 million by 2030, which underscores why the greater utilization of opioids for managing diverse sources of pain is directly stimulating the progression of the OIC therapeutic market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

What Are the Key Trends Driving Opioid-Induced Constipation Treatment Market Growth?
Key industry players within the sector focused on treating opioid-induced constipation are increasingly employing a strategy involving collaborative alliances to foster the creation of novel pharmaceuticals. These alliances benefit firms in the opioid-induced constipation treatment arena by pooling essential resources and specialized knowledge, thereby boosting their capacity for scientific investigation and product creation, broadening their market presence, and speeding up the process of bringing products to market, all of which contribute to heightened progress and expansion across the opioid-induced constipation treatment landscape. A concrete illustration of this strategy occurred in November 2022 when the Japanese biotech firm, Kyowa Kirin Co. Ltd, entered into an agreement with the German pharmaceutical entity, Grünenthal GmbH, with the shared objective of implementing integrated solutions for patient care. This cooperation is designed to advance the expansion and worldwide distribution of a collection of transformative medications aimed at pain management, encompassing therapies for constipation resulting from opioid use, acute cancer-related discomfort, and bone density loss.

How Is the Opioid-Induced Constipation Treatment Market Segmented?
The opioid-induced constipation treatmentmarket covered in this report is segmented -

1) By Drug Class: Laxatives; Peripherally Acting μ-opioid Receptor Antagonists; Serotonin Receptor Agonists; Prostaglandin
2) By Type: Oral; Parenteral
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies

Subsegments:
1) By Laxatives: Osmotic Laxatives; Stimulant Laxatives; Bulk-Forming Laxatives
2) By Peripherally Acting μ-Opioid Receptor Antagonists: Naloxegol; Methylnaltrexone; Alvimopan
3) By Serotonin Receptor Agonists: Prucalopride; Tegaserod
4) By Prostaglandin: Lubiprostone

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

Which Companies Are Leading the Charge in Opioid-Induced Constipation Treatment Market Innovation?
Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC

Which Regions Are Leading the Global Opioid-Induced Constipation Treatment Market in Revenue?
North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15881

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.